FDAnews Drug Daily Bulletin

PAIN THERAPEUTICS ENDS DEVELOPMENT OF BOWEL DRUG

Dec. 14, 2005
A A

Pain Therapeutics Inc. (PTIE.O: Quote, Profile, Research) said on Friday it will discontinue development of its experimental treatment for irritable bowel syndrome after a pivotal-stage trial failed to show that the drug is effective. The company said a Phase III trial of the drug, known as PTI-901, showed meaningful relief of symptoms in the second month of treatment, but the drug did not demonstrate a meaningful benefit in the third month of treatment, which was the trial's primary goal.

Reuters (http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=mtfh66836_2005-12-10_01-48-19_n09236544_newsml)